CLAVIS PHARMA - SHARE OPTION PLAN>
CLAVIS PHARMA - SHARE OPTION PLAN
(Thomson Reuters ONE) - Clavis Pharma ASA has a Share Option Plan where options are grantedonce annually. In accordance with the plan, the Board of ClavisPharma ASA has on 30 June 2009 awarded in total 340.200 share optionsto the following primary insiders: OptionsName Position Options granted new balanceKeith McCullagh Chairman of the Board 175 000 175 000Geir Christian Chief Executive 50 000 150 000Melen OfficerOle Henrik Eriksen Chief Operating 28 800 52 800 OfficerJan Alfheim Chief Business Officer 28 800 74 800Gunnar Manum Chief Financial 28 800 52 800 OfficerBo I. Nilsson Chief Medical Officer 28 800 52 800In addition, 100.800 share options have been awarded to employeesthat are not defined as primary insiders.The share options have a strike price of NOK 16.70 equal to theclosing trading price of the shares at the date of awarding the shareoptions. The exercise period for the share options is from 1 July2010 to 30 June 2012.ContactsGeir Christian Melen, CEOOffice : +47 24 11 09 65Mobile : +47 91 30 29 65E-mail : geir.christian.melen(at)clavispharma.comGunnar Manum, CFOOffice : +47 24 11 09 71Mobile : +47 95 17 91 90E-mail : gunnar.manum(at)clavispharma.comAbout Clavis PharmaClavis PharmaClavis Pharma ASA is an oncology focused pharmaceutical company usingits proprietary Lipid Vector Technology (LVT) platform to create NewChemical Entities (NCEs), by significantly improving alreadyestablished drugs. The improvements are achieved by chemicallybinding specific unsaturated lipids to existing, and well understood,approved pharmaceuticals. Data generated suggests the resultingpatentable NCEs offer improved efficacy and reduced side effectsthrough enhanced pharmacokinetic properties, greater tissuepenetration and, in many cases, additional modes of action.Clavis Pharma's objective is to develop its drug candidates untilsignificant value has been created and proof of principle in man hasbeen shown. For further clinical development and commercialisation ofthe products, Clavis Pharma will enter into strategic partnershipswith established pharmaceutical or biotech companies. The company'sproduct portfolio includes four new cancer drugs: Elacytarabine is inClinical Phase II, Intravenous CP-4126 is in Clinical Phase II, OralCP-4126 in Phase I, and CP-4200 is in preclinical development.Results indicate that these products have promising potential forseveral cancer indications within solid tumours and leukaemia.The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange(ticker: CLAVIS). Additional information on Clavis Pharma can befound at: http://www.clavispharma.com.DisclaimerThe information contained herein shall not constitute an offer tosell or the solicitation of an offer to buy, nor shall there be anysale of the securities referred to herein in any jurisdiction inwhich such offer, solicitation or sale would be unlawful prior toregistration, exemption from registration or qualification under thesecurities laws of any such jurisdiction.This news release contains forward-looking statements and forecastsbased on uncertainty, since they relate to events and depend oncircumstances that will occur in the future and which, by theirnature, will have an impact on results of operations and thefinancial condition of Clavis Pharma. There are a number of factorsthat could cause actual results and developments to differ materiallyfrom those expressed or implied by these forward-looking statements.Theses factors include, among other things, risks associated withtechnological development, the risk that research & development willnot yield new products that achieve commercial success, the impact ofcompetition, the ability to close viable and profitable businessdeals, the risk of non-approval of patents not yet granted anddifficulties of obtaining relevant governmental approvals for newproducts.No expressed or implied representations or warranties are givenconcerning Clavis Pharma or the accuracy or completeness of theinformation or projections provided herein, and no claims shall bemade by the recipient hereof by virtue of this Information Memorandumor the information or projections contained herein. Anyrepresentations or warranties made to an investor in Clavis Pharmawill be subject to separate sale and purchase agreements to benegotiated between the parties.Clavis Pharma(TM) is a registered trademark of Clavis Pharma ASA.http://hugin.info/136972/R/1326298/312120.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Leading Norwegian VoIP Provider Offers LG-Nortel Multimedia Terminal>
">Datum: 01.07.2009 - 02:12 Uhr
Sprache: Deutsch
News-ID 1002307
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 177 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CLAVIS PHARMA - SHARE OPTION PLAN>
"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
